23-04-2026, 17:02

Making the Commute Worth It: Lessons from a top 1% Workplace

Notified -
Globe Newswire23-04-2026, 17:02
8-01-2026, 22:27

SearchneedsLOVE Disrupts Digital Advertising Market with Global Launch of Accountability-Driven SEO Platform

Notified -
Globe Newswire8-01-2026, 22:27
10-04-2025, 16:38

Business: Blackshape unveils the Prime Xplorer at Aero 2025

Notified -
Globe Newswire10-04-2025, 16:38
31-03-2025, 18:15

L3Harris’ Commercial Aviation Solutions (CAS) Business, now known as Acron Aviation

Notified -
Globe Newswire31-03-2025, 18:15
2-01-2025, 19:48

Intesa Sanpaolo leads the Eurozone by market capitalisation

Notified -
Globe Newswire2-01-2025, 19:48
31-07-2024, 04:17

Poste Italiane net profit exceeds €1 bln in first half of 2024; CEO: successful business model
Globe Newswire31-07-2024, 04:17
1-07-2024, 20:00

In Rapid Rise of AI, Employers Turn to Business School Graduates for Human Skills
Globe Newswire1-07-2024, 20:00
11-06-2024, 01:33

London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024
Globe Newswire11-06-2024, 01:33
11-06-2024, 01:33

London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024

Notified -
Globe Newswire11-06-2024, 01:33
18-04-2024, 04:07

Unveiling the 8th Future Investment Initiative’s theme: "Infinite Horizons: Investing Today, Shaping Tomorrow"
Globe Newswire18-04-2024, 04:07
15-04-2024, 19:00

London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami
Globe Newswire15-04-2024, 19:00
15-04-2024, 19:00

London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami

Notified -
Globe Newswire15-04-2024, 19:00